Journal of Neurology, Neurosurgery, and Psychiatry 2008;79:490; doi:10.1136/jnnp.2007.135350
Copyright © 2008 by the BMJ Publishing Group Ltd.
Should we accept the status quo? Time for new trials in status epilepticus
Margaret J Jackson
Correspondence to:
Dr M J Jackson, Department of Neurology, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne NE1 4LP, UK; margaret.jackson@ncl.ac.uk
| The first 150 words of the full text of this article appear below. |
Status epilepticus (SE), defined as a seizure or series of seizures without recovery between lasting more than 30 min, takes a variety of forms, as illustrated in the report by Knake and colleagues1 in this issue of J Neurol Neurosurg Psychiatry (see page 588). In their paper, the response to intravenous levetiracetam of 16 patients with a total of 18 episodes of status epilepticus is described. The patients were all adults; the majority of episodes of SE were complex partial and symptomatic in aetiology, a case mix that might well be seen in an acute medical admissions unit. The duration of SE is not given, a pity particularly for the patients with convulsive SE where outcome is related to duration of seizure activity. All patients received intravenous benzodiazepine, usually lorazepam, before levetiracetam. Intravenous levetiracetam was given as a bolus dose of 250–1500 mg and was associated with seizure . . . [Full text of this article]
Related Article
-
Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus
- S Knake, J Gruener, K Hattemer, K M Klein, S Bauer, W H Oertel, H M Hamer, and F Rosenow
J. Neurol. Neurosurg. Psychiatry 2008 79: 588-589.
[Abstract]
[Full Text]
[PDF]
Terms and conditions relating to subscriptions purchased online ¦ Website terms and conditions ¦ Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.